Please try another search
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.
Name | Age | Since | Title |
---|---|---|---|
Patrick Donald Davies | - | 2018 | Independent Non-Executive Chairman |
Dianne M. Angus | 61 | 2018 | Independent Non-Executive Director |
Jenny Lee Harry | - | 2018 | Independent Non-Executive Director |
Trevor Donald Scott | - | 2002 | Independent Non-Executive Director |
Joe Basile | - | 2023 | Independent Non-Executive Director |
Jonathan Charles Pilcher | - | 2013 | CEO, MD & Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review